Literature DB >> 8636012

Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens.

Y Hattori1, H Tashiro, T Kawamoto, Y Kodama.   

Abstract

The aim of this study was to estimate the validity of mass screening for gastric cancer using serum pepsinogens (PG test). The study subjects were 4876 workers aged from 40 to 61 years old. Sera were obtained at the time of the health checkup and serum pepsinogen levels (PG I and PG II) were measured at the same time. PG I < 50 ng/ml and PG I/PG II ratio < 3.0 were adopted as the criteria for a positive result for the PG test. PG test-positive subjects were examined, in principle, by endoscopy. Furthermore, all subjects were followed up for a year to check for occurrence of gastric cancer. Among the total subjects, 911 (18.7%) were positive for the PG test and 650 (71.4%) among the positive subjects underwent further examinations, which revealed 11 cases of gastric cancer. Seven gastric cancer cases were diagnosed during the follow-up period within one year after the PG test. When the results of one years's follow-up from the time of screening were defined as the gold standard, the sensitivity and specificity of the PG test were estimated at 66.7% and 81.5%, respectively. The authors conclude that the validity of the PG test as a mass screening method may be comparable to that of X-ray screening, if optimum criteria of a positive test are selected.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8636012      PMCID: PMC5920667          DOI: 10.1111/j.1349-7006.1995.tb03317.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

1.  Estimation of validity of mass screening program for gastric cancer in Osaka, Japan.

Authors:  R Murakami; H Tsukuma; T Ubukata; K Nakanishi; I Fujimoto; T Kawashima; H Yamazaki; A Oshima
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

2.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

3.  Evaluation of a mass screening program for stomach cancer with a case-control study design.

Authors:  A Oshima; N Hirata; T Ubukata; K Umeda; I Fujimoto
Journal:  Int J Cancer       Date:  1986-12-15       Impact factor: 7.396

4.  [Estimation of frequency, population doses and stochastic risks in stomach mass screening examinations in Japan, 1980].

Authors:  T Maruyama; Y Noda; Y Kumamoto; K Nishizawa; Y Furuya; K Iwai; S Urahashi; R Kurihara; R Kamata; S Sakata
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1987-07-25

5.  A clinical and statistical follow-up study of atrophic gastritis.

Authors:  R Cheli; L Santi; G Ciancamerla; G Canciani
Journal:  Am J Dig Dis       Date:  1973-12

6.  Serum pepsinogens as a screening test of extensive chronic gastritis.

Authors:  K Miki; M Ichinose; A Shimizu; S C Huang; H Oka; C Furihata; T Matsushima; K Takahashi
Journal:  Gastroenterol Jpn       Date:  1987-04

7.  Chronic gastritis in Japanese with reference to high incidence of gastric carcinoma.

Authors:  T Imai; T Kubo; H Watanabe
Journal:  J Natl Cancer Inst       Date:  1971-07       Impact factor: 13.506

8.  Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample.

Authors:  P Sipponen; M Kekki; M Siurala
Journal:  Cancer       Date:  1983-09-15       Impact factor: 6.860

9.  Serum pepsinogen I as a predictor of stomach cancer.

Authors:  A M Nomura; G N Stemmermann; I M Samloff
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

10.  The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects.

Authors:  K Miki; M Ichinose; N Kawamura; M Matsushima; H B Ahmad; M Kimura; J Sano; T Tashiro; N Kakei; H Oka
Journal:  Jpn J Cancer Res       Date:  1989-02
View more
  21 in total

1.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

2.  Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.

Authors:  Shigeto Mizuno; Masao Kobayashi; Shohken Tomita; Ikuya Miki; Atsuhiro Masuda; Mitsuko Onoyama; Yasuki Habu; Hideto Inokuchi; Yoshiyuki Watanabe
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

Review 3.  How to assess the severity of atrophic gastritis.

Authors:  Yan-Cheng Dai; Zhi-Peng Tang; Ya-Li Zhang
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

4.  Simultaneous detection of different serum pepsinogens and its primary application.

Authors:  Jue Zhang; Ji-Zhong Guo; Hua-Long Xiao; Lan Zhu; Hai-Yan Liu; Yi Zhang; Biao Huang
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

5.  Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.

Authors:  Ju Yup Lee; Kyung Sik Park; Hyun-Gyo Lee; Won-Ki Baek; Kwang Bum Cho; Yoo Jin Lee; Yoon Suk Lee; Seung-Wan Ryu
Journal:  Clin Exp Med       Date:  2016-05-06       Impact factor: 3.984

Review 6.  Implementation of gastric cancer screening - the global experience.

Authors:  Mārcis Leja; Weicheng You; M Constanza Camargo; Hiroshi Saito
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-09-28       Impact factor: 3.043

7.  Novel risk markers for gastric cancer screening: Present status and future prospects.

Authors:  Shotaro Enomoto; Takao Maekita; Hiroshi Ohata; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

8.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

9.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

10.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.